<DOC>
	<DOCNO>NCT00539461</DOCNO>
	<brief_summary>In German non-interventional observational study 1980 patient diagnose Restless Legs Syndrome ( RLS ) investigate 990 General Practitioners across federal state Germany . Both moderate severe RLS patient , without previous RLS treatment , suffer RLS symptom like desire move extremity usually associate discomfort , motor restlessness worsen symptom rest least temporary relief activity , worsen symptom later day night , eligible study , plan initiate therapy pramipexole add pramipexole previously give , insufficient therapy . Three visit plan document PMS study , one baseline visit , visit two end pramipexole titration visit three 12 week treatment . Evaluations visit carry documented part routine medical practice . The main goal observational study determine pramipexole treatment work apply actual practice thus maximise external validity . In actual practice patient exclude clinical registration trial PPX moderate severe primary RLS ( i.e . certain disease history , co-morbidities and/or demographic characteristic ) treat PPX . Thus addition observational study information efficacy safety PPX patient obtain . The objective PMS study : - To evaluate treatment effect pramipexole RLS severity general improvement measure IRLS CGI-I . - To evaluate quality life RLS patient measure Restless Legs Syndrome Quality Life questionnaire ( RLS-QoL ) . - To evaluate safety profile PPX natural study population .</brief_summary>
	<brief_title>Non-interventional Observational Study Pramipexole Restless Legs Syndrome : Impact Quality Life</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>1 . Diagnosis primary RLS 2 . Indication RLS treatment Sifrol® ( pramipexole ) 3 . Male female patient age least 18 year . 1 . Any contraindication accord Summary Product Characteristics ( SPC ) : hypersensitivity pramipexole excipients . 2 . Ongoing treatment Sifrol® ( pramipexole ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>